Key Takeaways
- The UK's services sector showed robust growth in August, pushing the Composite PMI to a one-year high of 53.0, despite a continued contraction in manufacturing.
- The Eurozone's manufacturing sector unexpectedly returned to expansion in August, with its PMI rising to 50.5, while services activity saw a slight decline.
- Demand for Novo Nordisk's (NVO) Wegovy is expected to receive an unexpected boost in the UK following rival Eli Lilly's (LLY) decision to significantly raise the price of its competing obesity drug, Zepbound.
- Switzerland's gold exports to the United States surged to a 13-year high in January, driven by market uncertainty surrounding U.S. trade policies, impacting the bilateral trade balance.
The latest Purchasing Managers' Index (PMI) data for August reveals a mixed economic picture across Europe, with the UK's service sector demonstrating resilience while its manufacturing counterpart struggles. Meanwhile, the Eurozone saw its manufacturing sector unexpectedly expand, even as services activity softened. Beyond macroeconomic indicators, significant developments are unfolding in the pharmaceutical and global trade sectors.
UK Economic Performance: Services Bolster Composite PMI
British businesses experienced their strongest month in a year in August, primarily driven by a rebound in the dominant services sector. The preliminary S&P Global HCOB Services PMI for August rose to 53.6, significantly exceeding both the estimated 51.8 and July's 51.8 reading, marking a 12-month high. This strong performance pushed the UK's Composite PMI to 53.0, up from 51.5 in July and above the forecast of 51.6, reaching its highest level since August of last year.
However, the manufacturing sector continued its contraction, with the Manufacturing PMI falling to 47.3 in August, missing the forecast of 48.3 and down from July's 48.0. This marks the lowest point for the manufacturing index in three months, with factories reportedly impacted by the global trade environment, including U.S. tariff uncertainty. While the overall economic growth pace accelerated over the summer, the demand environment remains uneven and fragile, with companies expressing concerns over recent government policy changes and broader geopolitical uncertainties. Furthermore, companies across both sectors continued to shed jobs, albeit at a slower pace than in July, and services firms increased prices at the fastest rate in three months, posing a challenge for the Bank of England's inflation management efforts.
Eurozone Economic Snapshot: Manufacturing Rebounds
The Eurozone's private sector activity also saw an increase in August, with the HCOB Composite PMI rising to 51.1, surpassing both the estimate of 50.6 and July's 50.9, reaching a 15-month high. This improvement was largely fueled by an unexpected expansion in the manufacturing sector. The Eurozone HCOB Manufacturing PMI climbed to 50.5 in August, exceeding the forecast of 49.5 and July's 49.8, marking a 38-month high and signaling a return to expansion.
Conversely, the Eurozone HCOB Services PMI saw a slight dip, falling to 50.7 in August from 51.0 in July, just below the forecast of 50.8, representing a two-month low. Despite the mixed sectoral performance, new orders across the Eurozone increased, ending a period of decline that stretched back to June 2024. Business activity picked up to its greatest extent in 15 months, and staffing levels continued to increase for the sixth consecutive month. However, inflationary pressures strengthened, with both input costs and output prices rising at sharper rates in August.
Pharmaceutical Market Dynamics: Eli Lilly's Price Hike Benefits Novo Nordisk
The competitive landscape in the weight-loss drug market is seeing a significant shift as Eli Lilly (LLY) announced a substantial price increase for its GLP-1 obesity drug, Zepbound, in the UK. The company plans to hike the UK price by 170% in 2025, with similar moves expected across other European markets. This decision by Eli Lilly follows a push from the Trump administration to reduce drug prices in the U.S. by encouraging price adjustments overseas.
This unexpected pricing strategy from a key rival is anticipated to provide a boost to demand for Novo Nordisk's (NVO) competing drug, Wegovy. While Novo Nordisk's workforce nearly doubled over the past five years due to the booming demand for Wegovy, the company is now facing slowing sales and recently implemented a global hiring freeze for non-critical roles, indicating potential future layoffs. Despite Eli Lilly being forecasted to overtake Novo Nordisk in the overall GLP-1 drug market in 2025, the recent 33% jump in Wegovy prescriptions in the U.S. (following an FDA ban on copycat versions) highlights the dynamic nature of this high-growth sector.
Global Trade and Gold: Switzerland's Exports to the US Soar
Switzerland's gold exports to the United States experienced a remarkable surge in January 2025, reaching their highest level in at least 13 years. Exports to the U.S. hit an astonishing 192.9 metric tons, a significant increase from 64.2 tons in December 2024. This surge is largely attributed to growing uncertainty over U.S. trade policies and traders' anticipation of potential tariffs, leading to increased gold deliveries to Comex-approved warehouses.
Despite gold now being exempt from tariffs, the significant flows of the precious metal continue to impact trade balance calculations between Switzerland and the U.S. The Swiss National Bank (SNB) has even suggested that gold trade should be excluded from bilateral trade balances, arguing that such movements reflect global financial motives rather than fundamental economic ties. The influx of gold into the U.S. has led to Comex gold stocks reaching their highest level since March 2021 and has widened the price premium between U.S. gold futures and London spot prices.
Australia's Economic Reforms
In other global news, Australia has announced plans to remove tariffs and simplify home permits following a recent summit. This initiative aims to streamline economic processes and boost key sectors.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.